AI Article Synopsis
- The EADV Task Forces analyzed the Health-Related Quality of Life (HRQoL) measurement in urticaria treatment, highlighting the Dermatology Life Quality Index as the most commonly used tool in clinical trials.
- Many trials lacked specific numeric results on HRQoL changes, complicating comparisons and conclusions across studies.
- The study suggests favoring HRQoL instruments that include minimal clinically significant difference (MCID) data for better relevance in clinical practice rather than just relying on statistically significant changes.
Article Abstract
In this study, the European Academy of Dermatology and Venereology (EADV) Task Forces on Quality of Life and Patient-Oriented Outcomes and Urticaria and Angioedema has examined the Health-Related Quality of Life (HRQoL) measurement in the treatment of urticaria. The Dermatology Life Quality Index was the most frequently used HRQoL instrument in clinical trials on urticaria. Many reports of clinical trials of urticaria gave no exact numeric results related to HRQoL changes, making clear conclusions and comparisons with other studies impossible. The interpretation of HRQoL impairment data is more difficult when assessed by instruments without severity stratification systems. The minimal clinically significant difference (MCID) is a more clinically oriented and relevant parameter than depending on statistically significant changes in HRQoL scores. Therefore, using HRQoL instruments with established MCID data in clinical trials and clinical practice is preferred.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ijd.17366 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!